Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, ...

Teva collaboration agreement aims to accelerate clinical data generation for TEV-56278 and develop Anti-PD1-IL2 Therapy.

TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.

New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

(NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, ...

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanomaFosun Pharma-Teva collaboration agreement established with g ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a research collaboration to develop predictive ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

I-Mab (NASDAQ: IMAB) (the "Company”), a U.S.-based, global biotech company, focused on the development of precision ...